Verified Nov 2026
Other
·
Malvern, Pennsylvania
·
Since 2012
TELA Bio, Inc. is a medical technology company headquartered in Malvern, Pennsylvania, founded in 2012, with roughly 200 to 500 employees. It is publicly traded on NASDAQ under the ticker TELA and serves the medical sector, focusing on soft-tissue reconstruction. Its flagship OviTex Reinforced Tissue Matrix is used for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company reported its second quarter 2026 financial results on August 10, 2026.
Tela Bio at a glance
Revenue
80.3M
Employees
200-500
Founded
2012
Headquarters
Malvern, Pennsylvania
Ownership
Publicly traded (NASDAQ: TELA)
Industries
Automotive
Electric Vehicles
Construction
Medical
Industrial Equipment
Overview
TELA Bio, Inc. is a medical technology company headquartered in Malvern, Pennsylvania, founded in 2012, with roughly 200 to 500 employees. It is publicly traded on NASDAQ under the ticker TELA and serves the medical sector, focusing on soft-tissue reconstruction. Its flagship OviTex Reinforced Tissue Matrix is used for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company reported its second quarter 2026 financial results on August 10, 2026.
At a glance
Attribute | Detail |
|---|---|
Founded | 2012 |
Headquarters | Malvern, Pennsylvania |
Employees | 200-500 |
Revenue | 80.3M |
Ownership | Publicly traded (NASDAQ: TELA) |
What Tela Bio makes
Its products combine minimally processed biologic layers with synthetic polymers, and the record lists plastic surgery among its product areas.
Products and capabilities described on the company's own site include Plastic (source: telabio.com).
Latest developments
2026-08-31 — TELA Bio Announces COO / CFO Transition and Strategic Cost (globenewswire.com)
2026-08-10 — TELA Bio Reports Second Quarter 2026 Financial Results | TELA Bio, Inc. (telabio.com)
2026-05-12 — TELA Bio Reports First Quarter 2026 Financial Results | TELA Bio, Inc. (telabio.com)
2026-04-30 — TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues | TELA Bio, Inc. (telabio.com)
2026-03-24 — TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results | TELA Bio, Inc. (telabio.com)
2025-11-13 — TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility | TELA Bio, Inc. (telabio.com)
Company details
The company was listed as having a revenue band of about 80.3 million and was reported to have added four commercial leaders to its board in April 2026. Tela Bio was founded in 2012, has an estimated 200-500 employees, and is headquartered in Malvern, Pennsylvania.
Frequently asked questions
What does Tela Bio do?
TELA Bio, Inc. is a medical technology company headquartered in Malvern, Pennsylvania, founded in 2012, with roughly 200 to 500 employees. It is publicly traded on NASDAQ under the ticker TELA and serves the medical sector, focusing on soft-tissue reconstruction. Its flagship OviTex Reinforced Tissue Matrix is used for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company reported its second quarter 2026 financial results on August 10, 2026.
Where is Tela Bio headquartered?
Tela Bio is headquartered in Malvern, Pennsylvania (1 Great Valley Pkwy, Malvern, Pennsylvania, 19355).
When was Tela Bio founded?
Tela Bio was founded in 2012.
How big is Tela Bio?
Tela Bio has an estimated 200-500 employees, with revenue in the 80.3M range.
Is Tela Bio publicly traded?
Publicly traded (NASDAQ: TELA). Public financial figures are drawn from its filings.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.